5. A new drug to treat psoriasis has been developed and is in clinical testing. Assume that those individuals given the drug are examined before receiving the treatment and then again after receiving the treatment to determine if there was a change in their symptom status. If the initial results showed that 9.0% of individuals entered the study in remission, 74.0% of individuals entered the study with mild symptoms, 13.0% of individuals entered the study with moderate symptoms, and 4.0% entered the study with severe symptoms calculate and interpret a chi-squared test to determine if the drug was effective treating psoriasis given the information below from the final examination.Remission (No Symptoms of Psoriasis)Mild Symptoms of PsoriasisModerate Symptoms of PsoriasisSevere Symptoms of PsoriasisTotal Number of Participants Page 3 of 4to Receive the DrugNumber of Participants4556358571182a. We reject H0 because 1273.142 is greater than 5.99. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. b. We reject H0 because 1273.142 is greater than 9.51. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective.c. We reject H0 because 1273.142 is greater than 7.81. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective.d. We reject H0 because 1273.142 is greater than 11.07. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effec

5. A new drug to treat psoriasis has been developed and is in clinical testing. Assume that those individuals given the drug are examined before receiving the treatment and then again after receiving the treatment to determine if there was a change in their symptom status. If the initial results showed that 9.0% of individuals entered the study in remission, 74.0% of individuals entered the study with mild symptoms, 13.0% of individuals entered the study with moderate symptoms, and 4.0% entered the study with severe symptoms calculate and interpret a chi-squared test to determine if the drug was effective treating psoriasis given the information below from the final examination.Remission (No Symptoms of Psoriasis)Mild Symptoms of PsoriasisModerate Symptoms of PsoriasisSevere Symptoms of PsoriasisTotal Number of Participants Page 3 of 4to Receive the DrugNumber of Participants4556358571182a. We reject H0 because 1273.142 is greater than 5.99. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. b. We reject H0 because 1273.142 is greater than 9.51. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective.c. We reject H0 because 1273.142 is greater than 7.81. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective.d. We reject H0 because 1273.142 is greater than 11.07. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effec

MATLAB: An Introduction with Applications

6th Edition

ISBN:9781119256830

Author:Amos Gilat

Publisher:Amos Gilat

Chapter1: Starting With Matlab

Section: Chapter Questions

Problem 1P

See similar textbooks

Related questions

Question

Page 3 of 4to Receive the DrugNumber of Participants4556358571182a. We reject H0 because 1273.142 is greater than 5.99. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective. b. We reject H0 because 1273.142 is greater than 9.51. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective.c. We reject H0 because 1273.142 is greater than 7.81. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effective.d. We reject H0 because 1273.142 is greater than 11.07. We have statistically significant evidence at the alpha equals .05 level to show that the distribution of the severity of psoriasis cases at the end of the clinical trial for the sample is different from the distribution of the severity of psoriasis cases prior to the administration of the drug, suggesting the drug is effec

Expert Solution

Trending now

This is a popular solution!

Step by step

Solved in 4 steps with 2 images

SEE SOLUTION Check out a sample Q&A here